Published in Asian J Transfus Sci on October 03, 2017
Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 17.57
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 10.39
The clinical course of neuromyelitis optica (Devic's syndrome). Neurology (1999) 8.03
Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol (2009) 4.88
Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain (2010) 3.95
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol (2009) 3.91
Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med (1999) 3.66
Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher (2010) 3.47
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol (2006) 3.26
NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology (2008) 3.21
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12
Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher (2013) 2.97
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80
A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol (1999) 2.69
EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol (2010) 2.45
Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology (2002) 2.41
Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol (1996) 2.41
Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology (2010) 1.75
Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol (1998) 1.56
Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol (2011) 1.49
Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler (2007) 1.45
Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry (2012) 1.42
Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler (2009) 1.41
Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler (2007) 1.37
Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurol Neurosurg Psychiatry (2011) 1.32
Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord (2011) 1.19
Sham procedures and the ethics of clinical trials. J R Soc Med (2004) 1.16
New insights into neuromyelitis optica. J Clin Neurol (2011) 1.09
Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. Neurology (2009) 1.09
Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study. Neurology (2011) 1.09
Devic's neuromyelitis optica during pregnancy in a patient with systemic lupus erythematosus. Lupus (1999) 1.07
Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol (2013) 1.01
Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler (2003) 0.97
Relapsing neuromyelitis optica: long term history and clinical predictors of death. J Neurol Neurosurg Psychiatry (2009) 0.95
[Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses: clinical experience with 16 patients]. Nervenarzt (2006) 0.94
Lymphocytaplasmapheresis in Devic's syndrome. Transfusion (1985) 0.92
The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci (2011) 0.89
Progressive necrotizing myelopathy: part of the spectrum of neuromyelitis optica? Neurol Res (2006) 0.84
Transverse myelitis in a patient with severe lupus nephritis: a case report. Saudi J Kidney Dis Transpl (2007) 0.81
Plasmapheresis in acute multiple sclerosis: rationale and results. J Clin Apher (1991) 0.79
Fulminant Devic disease successfully treated by lymphocytapheresis. J Neurol Neurosurg Psychiatry (2006) 0.77
Mixed connective tissue disease: recurrent episodes of optic neuropathy and transverse myelopathy. Successful treatment with plasmapheresis. J Neurol Sci (1994) 0.77